Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates ...
STAT20m
Eli Lilly seeks to join lawsuit on compounded drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
FiercePharma3d
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...
BioSpace1h
All About Speed: Lilly Drives Innovation With New Facility to Help Bring Medicines to Market
Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
BioSpace3d
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...
The Hill3d
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Following the FDA’s reaffirmation, 503B compounding pharmacies have until March 19 to stop selling compounded tirzepatide. In its motion filed on New Year’s Day, Eli Lilly stated it seeks to ...